Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
August 30, 2021 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile...
Bone Therapeutics annonce les résultats principaux de l'étude de Phase III évaluant son viscosupplément amélioré, le JTA-004, dans l'arthrose du genou
August 30, 2021 01:00 ET | Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Aucune différence statistiquement significative n’a été observée dans la réduction de la douleur du genou entre JTA-004, le placebo et le comparateur actif 3 mois après le...
Bone Therapeutics provides update on the progress of clinical studies
July 19, 2021 01:00 ET | Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
July 19, 2021 01:00 ET | Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Biosplice logo_final RGB 300 dpi_white background.png
Dave Johnson Joins Biosplice Therapeutics Board of Directors
June 21, 2021 09:15 ET | Biosplice Therapeutics, Inc.
SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Logo.png
New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsight
May 25, 2021 20:00 ET | DelveInsight Business Research LLP
Los Angeles, USA, May 25, 2021 (GLOBE NEWSWIRE) -- New Osteoarthritis Drugs Coming Down the Pipeline: A Clinical Trial Review by DelveInsightApproximately 80+ key companies are developing...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Publishes Successful Clinical Trial in Knee Osteoarthritis
April 26, 2021 09:15 ET | Biosplice Therapeutics, Inc.
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Licenses Rights to Lorecivivint, a Novel Phase 3 Osteoarthritis Drug Candidate, to Samil for the Republic of Korea
April 22, 2021 11:36 ET | Biosplice Therapeutics, Inc.
SAN DIEGO, April 22, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for...
Inotiv_Logo_CMYK.png
Inotiv, Inc. Announces Expansion of Pharmacology and Pathology Offerings with Agreement to Purchase Bolder BioPATH, Inc.
April 16, 2021 08:33 ET | Inotiv, Inc.
WEST LAFAYETTE, Ind., April 16, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of non-clinical and analytical contract research...
Bone Therapeutics completes recruitment and patient treatment in JTA-004 pivotal Phase III knee osteoarthritis study
December 22, 2020 01:00 ET | Bone Therapeutics SA
Topline results expected in Q3 2021 Gosselies, Belgium, 22 December 2020, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical...